Epizyme nets $20 million up front as GSK widens interest in epigenetics
This article was originally published in Scrip
Executive Summary
Epizyme will receive $20 million up front and potentially more than $630 million in milestone payments under an alliance with GlaxoSmithKline to discover, develop, and commercialise novel small molecule therapeutics targeting epigenetic enzymes for the treatment of cancer and other diseases.